Track topics on Twitter Track topics that are important to you
Subject: Temporary importation of cycloSERINE, 250 mg capsules to address shortage
January 07, 2019
Dear Healthcare Professional,
Due to an anticipated shortage of SEROMYCIN® - cycloSERINE capsules, 250mg in the United States (U.S.) market by the end of 2018, Macleods Pharmaceuticals Limited, India (Macleods) is co-ordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of cycloSERINE capsules, 250mg for patients in the United States. Macleods has initiated temporary importation of cycloSERINE capsules, 250 mg into the United States market. This drug product is marketed globally and is manufactured in India.
At this time no other entity except Macleods is authorized by the FDA to import cycloSERINE capsules, 250 mg in the United States. FDA has not approved Macleods cycloSERINE capsules, 250 mg in the United States.
Effective immediately, and during this temporary period, Macleods will offer the following version:
It is important to note the following: • The imported product and U.S. FDA-approved product (SEROMYCIN®) contain the same active ingredient (cycloSERINE), strength (250 mg), and dosage form (capsules). • Please note the difference in the imported capsules’ appearance. The imported cycloSERINE capsule is maroon-colored. The U.S.FDA-approved SEROMYCIN® (cycloSERINE) capsule has an opaque red cap and opaque grey body and is imprinted with “CHAO” and “F04”.
• The barcode may not register accurately on the U.S. scanning systems. Alternative procedures should be followed to assure that the correct drug product is being used and administered to individual patients. For example, institutions should consider manually inputting the product into their systems and confirm that barcode systems do no provide incorrect information when the product is scanned.
Please refer to the package insert for the FDA-approved cycloSERINE capsules for full prescribing information, including the Warning section for risk of CNS toxicity.
The product comparison table below highlights the differences between the FDA-approved SEROMYCIN (cycloSERINE) capsules and the imported cycloSERINE capsules.
To place an order, or if you have any questions about the information contained in this letter or the use of cycloSERINE capsules, 250 mg, please contact Macleods at 1-888-943-3210 between the hours of 8 a.m. and 5 p.m. (ET), or email at firstname.lastname@example.org.
To report adverse events or quality problems associated with the use of this product, please call Macleods at 1-888-943-3210 between the hours of 8 a.m. and 5 p.m. (ET), or email at email@example.com.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
• Complete and submit the report Online: www.fda.gov/medwatch/report.htm • Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htmor call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 (1-800-332-0178)
We urge you to contact our Medical Information Department at 1-888-943-3210 between the hours of 8 a.m. and 5 p.m. (ET), or email firstname.lastname@example.org. If you have any questions about the information contained in this letter or the safe and effective use of CycloSERINE capsules.
Dr Ashish Mungatiwar Executive President Medical Services Macleods Pharmaceuticals
Product Name and Description
cycloSERINE Capsules, 250mg
30 Capsules, Non-Child Resistant
Packs of 3x10
FDA Approved Product
|Seromycin (cycloSERINE) capsule, 250 mg
||cycloSERINE capsule, 250 mg
Cycloserine capsules USP, 250 mg
Pack Count: 30's carton pack NDC 33342-462-06
Macleods Pharmaceuticals Limited
Cycloserine Capsules, USP, 250 mg, Blister Pack × 30
Trecator (ethionamide tablets, USP)Tablets
Assess the mechanism of action of d-cycloserine (DCS) to guide development of other medications working via similar molecular targets.
The research team hopes to use brain imaging and mental testing to learn more about specific phobias and the treatment of phobia. When given directly prior to therapy sessions, D-cycloseri...
The purpose of this study is to investigate if the effectiveness of cognitive-behavioral therapy for post-traumatic stress disorder can be increased by combining it with D-cycloserine (TCC...
Pre-clinical studies in rats suggest that D-cycloserine is effective in the management of chronic neuropathic pain. This pilot study will attempt to determine the effect of D-cycloserine i...
This is a parallel-group, placebo-controlled trial examining the cognitive effects at weeks 1, 4, & 8 of once-weekly oral D-cycloserine 50 mg added to a stable dose of antipsychotic for 8 ...
d-cycloserine is used to treat multidrug-resistant tuberculosis. Its efficacy, contribution in combination therapy, and best clinical dose are unclear, also data on the d-cycloserine minimum inhibitor...
Over half of children receiving cognitive behavioral therapy (CBT) for obsessive compulsive disorder (OCD) do not fully remit. To improve response rates and enhance extinction learning, d-cycloserine ...
A 1-day fear memory in ethanol withdrawn (ETOH) rats is resistant to destabilization-reconsolidation process. However, d-cycloserine (DCS) reverts this disturbance. Considering that the formation of p...
Within the general nitrofuran carboxamide chemotype, chimera derivatives incorporating diversely substituted imidazoles attached via an alkylamino linker were synthesized. Antimycobacterial evaluation...
Mycobacterioses are a constant problem in backyard poultry, as well as pet birds. To date, no evidence of direct transmission of atypical bacilli between humans has been demonstrated, but it cannot be...
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...